A new aspirin may be the latest to join the armory of drugs against cancer, has shown great promise in fighting and shrinking 11 different types of human cancer cells, without harming normal cells.
The new designer drug curbed the growth of cancer cells including colon, pancreatic, lung, prostate, breast and leukemia according to a team from the City College of New York.
“The key components of this new compound are that it is very, very potent and yet it has minimal toxicity to the cells,” said Khosrow Kashfi, principle study investigator. Prolonged use of aspirin is known to pose its own dangers: side-effects ranging from bleeding ulcers to kidney failures. To resolve this, they created a hybrid of two earlier formulations, which they have called NOSH-aspirin.
No comments:
Post a Comment